ZC3H7B

Across TCGA pan-cancer cohorts, ZC3H7B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZC3H7B data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZC3H7B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZC3H7B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where ZC3H7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.602	0.918	.003	25	view →
LSCC	DFS	Tertile	II,III,IV	0.617	0.926	.003	18	view →
PDAC	OS	Median	III,IV	0.431	0.743	.031	6	view →
LUAD	DFS	Quartile	All	0.667	0.889	.013	4	view →
UCEC	DFS	Median	All	1.000	0.938	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZC3H7B–HNSC (OS)

Open the HNSC breakdown →